ST. LOUIS--(BUSINESS WIRE)--Galera Therapeutics, a drug development company focused on novel therapeutics to protect against the side effects and increase the effectiveness of cancer treatment, today announced it has completed a Series 1 financing led by BioGenerator. Also participating in the round is Galera Angels, LLC, an angel investment group, and Analytical Bio-Chemistry Laboratories, Inc. (ABC), of Columbia Missouri. Proceeds from the financing will be used to advance Galera’s lead program targeting the prevention of oral mucositis, and to further the development of the company’s proprietary platform for other cancer therapy side effects.
